COMMUNIQUÉS West-GlobeNewswire

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
12/11/2024
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC Announced agreement with Roche to [...]
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12/11/2024
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 [...]
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2024
12/11/2024
SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. [...]
Sanara MedTech Inc. Reports Third Quarter 2024 Results
12/11/2024
FORT WORTH, TX, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused [...]
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
12/11/2024
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients [...]
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
12/11/2024
Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders [...]
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
12/11/2024
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial [...]
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors
12/11/2024
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of [...]
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12/11/2024
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024 Topline data from [...]
Lifecore Biomedical to Present at Stephens Annual Investment Conference
12/11/2024
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs [...]
Psychemedics Corporation Reports Third Quarter 2024 Financial Results
12/11/2024
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September [...]
FibroGen Reports Third Quarter 2024 Financial Results
12/11/2024
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration [...]
Hyperfine, Inc. Reports Third Quarter 2024 Financial Results
12/11/2024
GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic [...]
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
12/11/2024
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded [...]
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12/11/2024
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE [...]
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
12/11/2024
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed [...]
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
12/11/2024
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of [...]
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
12/11/2024
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
12/11/2024
Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform [...]

Pages